三友医疗与韩国细基生物株式会社签署战略合作和经销协议

Core Viewpoint - The company has signed a strategic cooperation and distribution agreement with CGBio, granting exclusive rights to distribute Novosis products in mainland China, which is expected to enhance its competitive strength in the orthopedic biomaterials sector [1][3]. Group 1: Agreement Details - The agreement was signed on December 2, 2025, and grants the company exclusive, non-transferable rights for procurement, import, marketing, distribution, sales, promotion, and other commercialization activities for Novosis products in mainland China [1]. - The authorization is valid for six years from the date the products receive medical device registration from the National Medical Products Administration of China [1]. Group 2: Product Information - Novosis is a synthetic bone graft material composed of recombinant human bone morphogenetic protein BMP-2 and hydroxyapatite ceramic, packaged with a disposable syringe and needle [2]. - The product is produced through genetic engineering from human rhBMP-2 cDNA and is designed to promote new bone formation with strong osteoconductive and osteoinductive properties [2]. - It is widely used in various surgical repair and reconstruction applications, including spinal fusion, limb trauma, and oral surgery [2]. Group 3: Strategic Impact - Acquiring exclusive distribution rights for Novosis products will enrich the company's product line and enhance its positioning in the orthopedic biomaterials market, providing comprehensive surgical solutions for patients and doctors [3]. - This move is expected to positively impact the company's operations and overall competitiveness in the industry [3].